Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes.
2012
Experimental studies suggest that bone marrow-derived endothelial progenitor cells (EPCs) play an important role in the
maintenance of endothelial integrity and hemostasis. The number of circulating EPC has been shown to be inversely correlated with
cardiovascular risk factors and vascular function and to predict cardiovascular events independent of both traditional and non-traditional
risk factors. Thus, EPCs provide a clinical advantage over the use of other biomarkers as their measurement is directly associated with
endothelial function, and available evidence suggests that they are consistently and significantly associated with a spectrum of
cardiovascular complications, such as acute coronary syndromes and coronary artery disease. However, many issues in the field of EPC
isolation and identification, particularly in regards to the effective and unequivocal molecular characterization of these cells still remain
unresolved. In addition, simple EPC counts do not adequately describe cardiovascular disease risk. This limitation is attributable to
variation in the definition of EPCs, the number of existing cardiovascular risk factors in different patients as well as a difference in the
interaction between EPCs and other hematopoietic progenitor, inflammatory cells or platelets.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
60
Citations
NaN
KQI